Table 4. Neoplasms reported during whole study period.
| Indication for rhGH treatment | Sex | Age at the baseline (years) | Age at neoplasm diagnosis (years) | Neoplasm type | rhGH at the time of diagnosis | Relationship with rhGH | Action undertaken | Outcome |
|---|---|---|---|---|---|---|---|---|
| Malignant | ||||||||
| Organic GHD | female | 19 | 21 | craniopharyngioma recurrence*,† | yes | possible | rhGH stopped | ongoing |
| Organic GHD | male | 9 | 14 | craniopharyngioma recurrence† | yes | unlikely | rhGH interrupted | resolved |
| 17 | craniopharyngioma recurrence†,‡ | yes | unlikely | none | resolved | |||
| Organic GHD | female | 13 | 14 | craniopharyngioma recurrence*,† | yes | possible | rhGH stopped | resolved |
| 15 | craniopharyngioma recurrence† | yes | unlikely | none | resolved | |||
| 17 | craniopharyngioma recurrence†,§ | off-treatment | unlikely | none | resolved | |||
| Organic GHD | male | 7 | 8 | craniopharyngioma recurrence*,† | off-treatment | possible | rhGH stopped | resolved |
| Idiopathic GHD | male | 12 | 13 | medulloblastoma† | yes | unlikely | rhGH stopped | death |
| TS | female | 8 | 9 | ovarian dysgerminoma stage unspecified† | yes | not related | rhGH interrupted | resolved |
| Benign | ||||||||
| Idiopathic GHD | female | 9 | 9 | skin papilloma* | yes | possible | none | resolved |
| Idiopathic GHD | male | 6 | 8 | skin papilloma | yes | unlikely | none | resolved |
| Idiopathic GHD | male | 3 | 11 | skin papilloma | yes | not related | none | resolved |
| TS | female | 4 | 11 | neurofibroma | yes | not related | none | ongoing |
| TS | female | 10 | 13 | osteochondroma | yes | not related | none | ongoing |
*Evaluated as related to rhGH treatment,
†reported as SAE,
‡Epilepsy was reported as AE approximately 2 years after this was resolved (ongoing).
§CSF leak was reported as AE 6 days after this was resolved (resolved after 9 days).
GHD growth hormone deficiency, rhGH recombinant human growth hormone, TS Turner syndrome